Determination of the Efficacy of Slendertone® Face to Tone the Muscles of the Face and Reduce the Signs of Facial Aging
NCT ID: NCT01030380
Last Updated: 2009-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
108 participants
INTERVENTIONAL
2009-02-28
2009-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Treated group: Face device 20 minutes per day, 5 days per week for 12 weeks.
Control group: No NMES.
Both Groups: No changes to usual beauty routine, or use of beauty products with an anti-aging claim, or changes to usual diet or exercise habits over the course of the 12 week study period.
Assessments:
Ultrasound measurements of the zygomaticus major muscle were planned at Baseline, and at the end of Weeks 6 and 12.
Psychometric questionnaires at Baseline, end of Weeks 6 and 12.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Slendertone Face NMES
Slendertone Face 20 minutes/day, 5 days/week for 12 weeks.
Slendertone Face
Slendertone Face 20 minutes/day, 5 days/week for 12 weeks.
Control Group: No NMES
Control Group: No NMES over the course of 12 weeks.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Slendertone Face
Slendertone Face 20 minutes/day, 5 days/week for 12 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Visual signs of aging of the face
* Able and willing to complete all study assessments and to be followed for the full course of the study.
* Able to read, write and follow instructions in English.
* Able and willing to provide informed consent.
Exclusion Criteria
* Inadequate precaution or procedure to prevent pregnancy (women of child- bearing potential only).
* Individuals who have any implanted medical devices (pacemaker, pump, catheter, etc.)
* Current or history of a medical condition that would contraindicate treatment with the product, such as epilepsy, hernia, abdominal ulcer, diabetes, or other conditions which, in the opinion of the Investigator, would place the participant at risk.
* A current skin disease of any type at the test site (e.g. acne, eczema, psoriasis, burns, abrasions, etc.)
* Heavy alcohol consumption in the opinion of the investigator.
* A fever in the last 12 hours prior to the first application of the test device.
* History of heart disease.
* History of stroke.
* History of malignant disease.
* Insulin dependent diabetes.
* Concurrent medication likely to affect the response to the test article or confuse the results of the study (e.g. routine high dose use of any drugs that may artificially affect skin tone).
* Individuals who are currently participating in any other clinical. investigation, or who have participated in a study with the same indication within 1 year.
* Principal investigator for this study, or member of study staff.
* Individuals who have had facial surgery.
* Individuals who use BOTOX. (The latter two exclusions were applied because of the possibility of an altered anatomical or physiological background which may have interfered with the effectiveness of the treatment).
25 Years
55 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bio-Medical Research, Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Neurologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Hennessy, M.D.
Role: PRINCIPAL_INVESTIGATOR
Chief of Neurology, Galway University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bio-Medical Research, Ltd.
Galway, County Galway, Ireland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Coleman SR, Grover R. The anatomy of the aging face: volume loss and changes in 3-dimensional topography. Aesthet Surg J. 2006 Jan-Feb;26(1S):S4-9. doi: 10.1016/j.asj.2005.09.012.
Rexbye H, Petersen I, Johansens M, Klitkou L, Jeune B, Christensen K. Influence of environmental factors on facial ageing. Age Ageing. 2006 Mar;35(2):110-5. doi: 10.1093/ageing/afj031. Epub 2006 Jan 11.
Roubenoff R. Sarcopenia and its implications for the elderly. Eur J Clin Nutr. 2000 Jun;54 Suppl 3:S40-7. doi: 10.1038/sj.ejcn.1601024.
Branchet MC, Boisnic S, Frances C, Robert AM. Skin thickness changes in normal aging skin. Gerontology. 1990;36(1):28-35. doi: 10.1159/000213172.
Zimbler MS, Kokoska MS, Thomas JR. Anatomy and pathophysiology of facial aging. Facial Plast Surg Clin North Am. 2001 May;9(2):179-87, vii.
McMiken DF, Todd-Smith M, Thompson C. Strengthening of human quadriceps muscles by cutaneous electrical stimulation. Scand J Rehabil Med. 1983;15(1):25-8.
Charette SL, McEvoy L, Pyka G, Snow-Harter C, Guido D, Wiswell RA, Marcus R. Muscle hypertrophy response to resistance training in older women. J Appl Physiol (1985). 1991 May;70(5):1912-6. doi: 10.1152/jappl.1991.70.5.1912.
Bax L, Staes F, Verhagen A. Does neuromuscular electrical stimulation strengthen the quadriceps femoris? A systematic review of randomised controlled trials. Sports Med. 2005;35(3):191-212. doi: 10.2165/00007256-200535030-00002.
Porcari JP, Miller J, Cornwell K, Foster C, Gibson M, McLean K, Kernozek T. The effects of neuromuscular electrical stimulation training on abdominal strength, endurance, and selected anthropometric measures. J Sports Sci Med. 2005 Mar 1;4(1):66-75. eCollection 2005 Mar 1.
Quittan M, Wiesinger GF, Sturm B, Puig S, Mayr W, Sochor A, Paternostro T, Resch KL, Pacher R, Fialka-Moser V. Improvement of thigh muscles by neuromuscular electrical stimulation in patients with refractory heart failure: a single-blind, randomized, controlled trial. Am J Phys Med Rehabil. 2001 Mar;80(3):206-14; quiz 215-6, 224. doi: 10.1097/00002060-200103000-00011.
Vanderthommen M, Depresseux JC, Dauchat L, Degueldre C, Croisier JL, Crielaard JM. Spatial distribution of blood flow in electrically stimulated human muscle: a positron emission tomography study. Muscle Nerve. 2000 Apr;23(4):482-9. doi: 10.1002/(sici)1097-4598(200004)23:43.0.co;2-i.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BMR-09-2009
Identifier Type: -
Identifier Source: org_study_id